What Is IGF-1 LR3 and How Does It Work
IGF-1 LR3 (Long R3 IGF-1) is a synthetic, 83-amino-acid analogue of human insulin-like growth factor 1. It was engineered in the early 1990s as a laboratory research tool, not a drug candidate, by adding an arginine substitution at position 3 and a 13-amino-acid extension to the N-terminus of the native IGF-1 sequence. Those modifications dramatically reduce the molecule's binding affinity for IGF-binding proteins (IGFBPs) - the carrier proteins that normally sequester most circulating IGF-1 and limit how much reaches receptors. With that brake substantially removed, IGF-1 LR3 remains far more persistently bioactive in circulation than native IGF-1.
Once bound to the IGF-1 receptor, it activates two major downstream pathways: PI3K/Akt, which drives protein synthesis, and MAPK/ERK, which stimulates cell proliferation. In skeletal muscle research, this translates to activation of satellite cells and support for both muscle fiber hypertrophy and nutrient uptake - the basis for its use in body-composition and performance research contexts. It is worth being direct about what that mechanism means: IGF-1 LR3 is not a targeted "muscle-only" signal. The same PI3K/Akt and MAPK/ERK pathways it activates in muscle are active in essentially every cell type in the body, which is central to the safety discussion below.
Research Dosing
There is no dose for IGF-1 LR3 established by published human clinical trials - none exist. The ranges below reflect what is commonly cited in research-community protocols and informal practice, not clinical dosing data, and should be read as hedged reference points rather than guidance.
| Tier | Commonly Cited Range | Frequency | Route |
|---|---|---|---|
| Conservative | ~20–40mcg | Every other day, ~4 weeks | SubQ injection |
| Intermediate | ~50–80mcg | Daily or every other day, 4–6 weeks | SubQ injection |
| Upper research-community range | ~100–120mcg | Daily, up to ~6 weeks, then off-cycle | SubQ injection |
Hypoglycemia risk: IGF-1 LR3 mimics insulin's glucose-transport effect, moving glucose out of the bloodstream and into muscle tissue. Continuous or higher-dose use, especially in a fasted state, can produce dangerous drops in blood sugar. Because of this, most reported use is timed post-workout alongside a substantial carbohydrate intake rather than administered fasted, and monitoring blood glucose is a routine part of any responsible research protocol involving this compound.
Regulatory Status
IGF-1 LR3 is not FDA-approved for human use, has no USP or NF drug substance monograph, and is not a component of any FDA-approved human drug. It does not appear on the FDA's 503A bulk drug substance list, which means it cannot legally be compounded for human use by any registered pharmacy or outsourcing facility. Products sold as "IGF-1 LR3" - including any carried in the BioStackIQ shop - are marketed and sold strictly as research chemicals for laboratory research use only, not for human consumption. Between 2017 and 2022, the FDA issued numerous warning letters to companies marketing IGF-1 LR3 in bodybuilding, anti-aging, and "performance enhancement" products, citing distribution of an unapproved new drug. This is a legal and safety distinction that should not be glossed over: research-use framing does not indicate that a product has been evaluated by any regulator for human safety or efficacy.
What Research Shows
The original pharmacological characterization of Long R3 IGF-1 was published in 1992 by researchers at CSIRO in Australia, using in vitro (myoblast cell-culture) and animal models rather than human subjects. That work established the core mechanistic rationale still cited today: reduced IGFBP binding relative to native IGF-1 gives the analogue substantially greater and more sustained biological potency at a given concentration.
It is important to be precise about what evidence exists and what doesn't. No human clinical trials of IGF-1 LR3 itself have been published - the compound was designed as a laboratory tool, not developed through a drug-trial pipeline. The safety signal around elevated IGF-1 signaling comes instead from epidemiological research on native, endogenous IGF-1 levels in humans. Large prospective cohort data (the EPIC-Heidelberg study) found that higher circulating IGF-1 was associated with increased risk of breast cancer (relative risk 1.25) and prostate cancer (relative risk 1.31), consistent with IGF-1's role in promoting cell proliferation and inhibiting apoptosis via the same PI3K/Akt/mTOR pathway IGF-1 LR3 activates. Chronic excess IGF-1 signaling is also linked to acromegaly-like tissue changes, including jaw, hand, and cardiac enlargement, with long-term overexposure. These are legitimate, non-hypothetical concerns that should inform anyone's risk assessment of this compound - not marketing language to be waved away.
For how IGF-1 LR3 is discussed alongside other compounds in body-composition research protocols, see the peptide stacks for muscle growth guide.